The 2019 North Carolina Down Syndrome Conference covers the lifespan of an individual with Down syndrome and is a valuable resource serving all audiences. The conference includes a plenary speaker, resource exhibits, networking lunch, and 18 breakout sessions that bring information and resources to families, educators, healthcare providers, and older teens and adults with Down syndrome.
Presenter: Jamie Edgin, Ph.D
Dr. Jamie Edgin is a tenured Associate Professor and Co-Director of the Cognition and Neural Systems Program in the Department of Psychology at the University of Arizona. Her research centers on understanding the neurological basis for sleep, memory, and language impairment in developmental disorders, particularly Down syndrome (DS) and autism. She has received several awards for her work in intellectual and developmental disabilities, including the 2018 University of Arizona Koffler Prize, the Charles Epstein award from the National Down Syndrome Society, and the Inaugural David Cox “Rising Star” award from the LuMind IDSC Foundation. She is an expert in Developmental Cognitive Neuroscience, with several published works on sleep, memory, and neuroimaging in typical children, DS, and other at-risk groups. She has >40 published papers employing sleep and neurocognitive assessment, EEG/ERP, fMRI, and eyetracking methodologies in these populations. She serves on several editorial boards for leading national and international journals focused on developmental disability and regularly participates in grant review for various granting agencies. Dr. Edgin’s team has just finished data collection on the first longitudinal study to examine sleep disturbance and development in infants and toddlers with DS from 6-24 months of age. Further, she currently leads a NIH-funded multisite study to design and validate a new neuropsychological assessment tool for use in intellectual disabilities, the “Arizona Memory Assessment for Preschoolers and Special Populations.” She was instrumental in the design and validation of one important battery of cognitive tests validated specifically for use in DS: The Arizona Cognitive Test Battery.
The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.
The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2018 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.
CTAD 2019 will highlight the latest on trying to get these trials off the ground.
Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.
Prof. Judith Jaeger
PhD, MPA, President and Principal Scientist at CognitionMetrics, LLC
Dr. Jaeger is an internationally recognized clinical neuropsychologist and pharmaceutical executive. She was previously the Vice President for Clinical Trials at Cogstate, Inc, and Director Clinical Development at AstraZeneca Pharmaceuticals, Inc.
– Clinical and pharmaceutical development expert on cognitive, psychiatric and neurological disorders
– Sought after key opinion leader and scientific consultant to most (14 of top 25) major pharma companies and several CRO’s and biotechs working in neuroscience.
The night will be a cocktail-formal affair, with a live blues band, great food, original art, an open bar, and a lot of fun.
Tickets are $75 each or $125 for two tickets. You can buy tickets (or donate in lieu of buying tickets) by clicking on the link below.
LuMind IDSC Foundation is proud to be a Bronze sponsor of the 2020 DSAIA Conference. We are looking forward to reuniting with our Down syndrome affiliates on February 27th in sunny Orlando, Florida to continue collaborating in our shared goals of improving health and independence in individuals with Down syndrome. Swing by the LuMind IDSC Foundation @ Booth # 5 to learn more about the exciting research, LIFE-DSR and the new LuMind IDSC initiatives for the Down syndrome community.
Join Our Workshops
To register or find out more information about the conference go to the DSAIA website. Our thanks to DSAIA and the conference committee for their exceptional work organizing this important meeting.
World Down Syndrome Day (WDSD) is a global awareness day selected to signify the uniqueness of the three copies of the 21st chromosome. Join us in celebrating individuals with Down syndrome and their accomplishments. Let’s show the world how they soar!
Please visit www.lumindidsc.org/soar for more information.